The Cinchona alkaloids: a silicon-directed synthesis of some advanced intermediates
摘要:
N-Benzylmeroquinene aldehyde (5b) was prepared in 10 steps and 21% overall yield from benzylamine. The key transformations involved a stereoselective Lewis acid catalyzed Diels-Alder reaction to produce bicyclic amide 18, which in turn underwent a regioselective Baeyer-Villager oxidation to produce lactone 20. Acid-catalyzed ring opening with concomitant Peterson olefination afforded the meroquinene skeleton, which was converted in high yield to meroquinene aldehyde via a reduction/oxidation sequence. Treatment of this aldehyde with anions derived from 4-methylquinoline smoothly generated alcohols 23a,b, which on acetylation yielded the advanced Cinchona alkaloid intermediates 24a,b.
[EN] COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY [FR] COMPOSÉS AYANT UNE ACTIVITÉ D'ANTAGONISTE DES RÉCEPTEURS MUSCARINIQUES ET D'AGONISTE DES RÉCEPTEUR ADRÉNERGIQUES BÊTA 2
COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
申请人:CHIESI FARMACEUTICI S.p.A.
公开号:US20160235734A1
公开(公告)日:2016-08-18
Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
Copper-Catalyzed Diamination of Unactivated Alkenes With Electron-Rich Amino Sources
作者:Yang Li、Arshad Ali、Junchao Dong、Yu Zhang、Lili Shi、Qun Liu、Junkai Fu
DOI:10.1021/acs.orglett.1c01313
日期:2021.5.21
The catalytic intermoleculardiamination of unactivated alkenes with electron-rich amino sources is a challenge. Herein, by employing a directing-group strategy, a copper-catalyzeddiamination of unactivated alkenes was realized. Symmetrical diamines were efficiently produced in a highly diastereoselective manner with readily available dialkylamines as amino sources, while a one-pot and two-step operation
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
申请人:Chiesi Farmaceutici S.p.A.
公开号:US08980913B2
公开(公告)日:2015-03-17
Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
申请人:CHIESI FARMACEUTICI S.p.A.
公开号:US10004728B2
公开(公告)日:2018-06-26
Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
本文定义的式 I 化合物既是毒蕈碱受体拮抗剂,又是β2 肾上腺素能受体激动剂,可用于治疗支气管阻塞性疾病和炎症性疾病。
WILSON, STEPHEN R.;DI, GRANDI MARTIN J., J. ORG. CHEM., 56,(1991) N5, C. 4766-4772